Lytix Biopharma AS
OSE:LYTIX
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.68
12.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LYTIX stock under the Base Case scenario is 1.02 NOK. Compared to the current market price of 6.82 NOK, Lytix Biopharma AS is Overvalued by 85%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Lytix Biopharma AS
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LYTIX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Lytix Biopharma AS
Balance Sheet Decomposition
Lytix Biopharma AS
Current Assets | 63.3m |
Cash & Short-Term Investments | 50.5m |
Receivables | 12.8m |
Other Current Assets | 1k |
Non-Current Assets | 548k |
PP&E | 548k |
Current Liabilities | 12.5m |
Accounts Payable | 3.6m |
Other Current Liabilities | 8.9m |
Non-Current Liabilities | 41k |
Long-Term Debt | 41k |
Earnings Waterfall
Lytix Biopharma AS
Revenue
|
4m
NOK
|
Operating Expenses
|
-100.8m
NOK
|
Operating Income
|
-96.8m
NOK
|
Other Expenses
|
8.9m
NOK
|
Net Income
|
-87.9m
NOK
|
Free Cash Flow Analysis
Lytix Biopharma AS
NOK | |
Free Cash Flow | NOK |
In Q2, Lytix Biopharma highlighted promising results from their LTX-315 Phase II studies, including an 86% average tumor size reduction in basal cell carcinoma patients. A new neoadjuvant study, NeoLIPA, is set to begin, evaluating LTX-315 with pembrolizumab in early-stage melanoma, aiming for a 40% response rate. The company raised NOK 50 million, extending their cash runway into 2025, and reported cash of NOK 60 million at quarter-end. Overall, Lytix is well-positioned to pursue commercialization opportunities as it continues to produce encouraging clinical data.
What is Earnings Call?
LYTIX Profitability Score
Profitability Due Diligence
Lytix Biopharma AS's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Lytix Biopharma AS's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
LYTIX Solvency Score
Solvency Due Diligence
Lytix Biopharma AS's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Lytix Biopharma AS's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LYTIX Price Targets Summary
Lytix Biopharma AS
According to Wall Street analysts, the average 1-year price target for LYTIX is 16.32 NOK with a low forecast of 16.16 NOK and a high forecast of 16.8 NOK.
Dividends
Current shareholder yield for LYTIX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.
Officers
The intrinsic value of one LYTIX stock under the Base Case scenario is 1.02 NOK.
Compared to the current market price of 6.82 NOK, Lytix Biopharma AS is Overvalued by 85%.